Envista Holdings Co. (NYSE:NVST) Receives Average Recommendation of “Hold” from Brokerages

Shares of Envista Holdings Co. (NYSE:NVST) have been assigned a consensus recommendation of “Hold” from the fifteen research firms that are covering the company, MarketBeat.com reports. Two equities research analysts have rated the stock with a sell rating, ten have issued a hold rating and three have given a buy rating to the company. The average twelve-month price target among brokerages that have issued ratings on the stock in the last year is $20.13.

Several research analysts have recently commented on the stock. Stifel Nicolaus increased their price target on shares of Envista from $18.00 to $21.00 and gave the stock a “buy” rating in a research note on Wednesday, October 23rd. Piper Sandler increased their price target on shares of Envista from $16.00 to $17.00 and gave the stock a “neutral” rating in a research note on Thursday, October 31st. Leerink Partners upgraded shares of Envista from an “underperform” rating to a “market perform” rating and increased their price target for the stock from $16.00 to $23.00 in a research note on Thursday, October 31st. Leerink Partnrs upgraded shares of Envista from a “strong sell” rating to a “hold” rating in a research note on Thursday, October 31st. Finally, Mizuho initiated coverage on shares of Envista in a research note on Wednesday, December 4th. They set an “underperform” rating and a $20.00 price target on the stock.

Envista Stock Up 0.2 %

Envista stock opened at $21.42 on Friday. The firm has a market cap of $3.69 billion, a PE ratio of -2.76, a P/E/G ratio of 1.88 and a beta of 1.33. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.77 and a current ratio of 2.08. The firm’s 50 day moving average price is $20.10 and its two-hundred day moving average price is $18.96. Envista has a twelve month low of $15.15 and a twelve month high of $24.79.

Envista (NYSE:NVST) last announced its quarterly earnings results on Wednesday, October 30th. The company reported $0.12 EPS for the quarter, topping the consensus estimate of $0.09 by $0.03. Envista had a negative net margin of 53.42% and a positive return on equity of 3.76%. The company had revenue of $601.00 million for the quarter, compared to analyst estimates of $590.34 million. During the same quarter in the prior year, the business posted $0.43 EPS. Envista’s quarterly revenue was down 4.8% on a year-over-year basis. On average, research analysts predict that Envista will post 0.72 EPS for the current fiscal year.

Institutional Trading of Envista

A number of hedge funds have recently bought and sold shares of the stock. Ariel Investments LLC boosted its holdings in Envista by 11.0% in the 2nd quarter. Ariel Investments LLC now owns 9,871,152 shares of the company’s stock valued at $164,157,000 after purchasing an additional 978,952 shares during the period. Nuance Investments LLC boosted its holdings in Envista by 4.4% in the 3rd quarter. Nuance Investments LLC now owns 7,346,534 shares of the company’s stock valued at $145,168,000 after purchasing an additional 308,221 shares during the period. Clarkston Capital Partners LLC lifted its holdings in shares of Envista by 0.4% during the 3rd quarter. Clarkston Capital Partners LLC now owns 4,347,300 shares of the company’s stock worth $85,903,000 after acquiring an additional 17,085 shares during the period. Franklin Resources Inc. lifted its holdings in shares of Envista by 26.5% during the 3rd quarter. Franklin Resources Inc. now owns 3,971,662 shares of the company’s stock worth $78,480,000 after acquiring an additional 830,861 shares during the period. Finally, Pacer Advisors Inc. lifted its holdings in shares of Envista by 22.2% during the 3rd quarter. Pacer Advisors Inc. now owns 3,529,827 shares of the company’s stock worth $69,749,000 after acquiring an additional 642,401 shares during the period.

About Envista

Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products.